Pieris Pharmaceuticals Announces Presentation Of Encouraging Preclinical Data For PRS-400 At ATS 2023 International Conference
Portfolio Pulse from Benzinga Newsdesk
Pieris Pharmaceuticals presented encouraging preclinical data for PRS-400, an inhaled therapy for muco-obstructive lung diseases, at the ATS 2023 International Conference. The data showed that PRS-400 reached desired potency goals and demonstrated in vivo proof of concept. PRS-400 is expected to advance to clinical development later this year.
May 22, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pieris Pharmaceuticals' PRS-400 shows promising preclinical data, potentially advancing the inhaled therapy for muco-obstructive lung diseases to clinical development later this year.
The positive preclinical data for PRS-400 indicates that the therapy has reached desired potency goals and demonstrated in vivo proof of concept. This is likely to boost investor confidence in Pieris Pharmaceuticals and may have a positive short-term impact on the stock price as the company advances towards clinical development later this year.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100